- News & Analysis
- Home
- Latest News
- Reports
- Podcast
- The CVC Funding Round Database
- The CVC Directory
- University
- Video
- Subscribe
- Newsletters
- Events
Page 97
Public markets greet eHi for $120m IPO
China-based car rental service eHi has secured $120m from its initial public offering and $50m from a private placement, as travel site Ctrip invested another $20m.
Nov 19, 2014Astellas-backed FibroGen goes public
The bioopharmaceutical company raised $145.8m in its initial public offering, while AstraZeneca invested $20m in a concurrent private placement.
Nov 17, 2014Gumi to float at $900m valuation
The mobile games company, which has raised $99m from backers including Gree, NTT Docomo, Sega, Zyga, Tecmo Koei and Nissei, plans to list in Japan next month.
Nov 17, 2014Hortonworks to go public in $100m IPO
The big data platform, which has raised nearly $250m from backers including Yahoo, HP and Teradata, plans to use the proceeds to expand its sales network.
Nov 13, 2014Lending platform OnDeck files for $150m IPO
OnDeck, which uses big data to lend to small businesses, has raised almost $100m in equity from investors including SAP and Google.
Nov 13, 2014Crowdworks to source markets for $9m IPO
The crowdsourcing platform, backed by CyberAgent, Digital Garage, Dentsu and Itochu, has secured about $14.5m in funding since it was founded in 2011.
Nov 11, 2014Sky Solar lowers IPO target by almost $100m
The solar power provider slashed its initial public offering from $150m to $55.2m after suspending it citing market conditions.
Nov 11, 2014Coherus secures $85m from IPO
The biosimilar developer, backed by Eli Lilly, Daaichi Sankyo and Medpace, will use the proceeds from its initial public offering to advance three of its product candidates.
Nov 10, 2014Nevro stimulates market for $126m IPO
Shareholders Novo and Johnson & Johnson invested a total of $4.6m as the neurostimulation device maker went public in a flotation that could rise to almost $145m.
Nov 10, 2014Inotek eyes $132m in public and debt offerings
The MedImmune-backed glaucoma treatment developer aims to raise up to $86.3m from its initial public offering, as well as an additional $46m in convertible debt.
Nov 7, 2014About us
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
Navigation
test regLogin
Not yet subscribed?
We use cookies to enhance your browsing experience and analyse our traffic. By clicking "Accept All", you consent to our use of cookies. Accept Read MorePrivacy & Cookies PolicyPrivacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.


